FindTrial
Sign In

Pembrolizumab (KEYTRUDA ®)

DRUG3 trials

Sponsors

NGM Biopharmaceuticals, Inc, Flare Therapeutics Inc., Groupe Oncologie Radiotherapie Tete et Cou

Conditions

Advanced Urothelial CarcinomaBladder Urothelial CancerBreast CancerCervical CancerCholangiocarcinomaColorectal CancerEndocervical CancerEsophageal Cancer

Phase 1

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Active, not recruitingNCT05311618
NGM Biopharmaceuticals, IncBladder Urothelial Cancer, Breast Cancer, Cervical Cancer +13
Start: 2022-05-11End: 2025-06-30Target: 71Updated: 2024-04-01
A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
RecruitingNCT05929235
Flare Therapeutics Inc.Advanced Urothelial Carcinoma, Open Label, Oral Drug Administration
Start: 2023-08-24End: 2028-01-30Target: 120Updated: 2026-01-30

Phase 3

Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN
Not yet recruitingNCT07264075
Groupe Oncologie Radiotherapie Tete et CouSquamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Start: 2026-04-01End: 2030-05-01Target: 780Updated: 2026-04-02

Related Papers

A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial.
2026-02-28
PPARG protein expression in advanced urothelial carcinoma and selection for response to FX-909, a first-in-class PPARG-targeting agent.
Journal of Clinical Oncology2025-02-10
Abstract A024: Genomic peroxisome proliferator-activated receptor gamma (PPARG) study: A sponsored testing program to identify patients harboring genetic alterations in advanced UC in support of the FX-909 Phase 1 study
Clinical Cancer Research2024-05-172 citations
A phase 1, first-in-human, dose-escalation and expansion study of FX-909 in patients with advanced solid malignancies, including advanced urothelial carcinoma.
Journal of Clinical Oncology2024-01-294 citations